Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 25 10 2018
revised: 09 01 2019
accepted: 16 01 2019
pubmed: 21 1 2019
medline: 21 5 2019
entrez: 21 1 2019
Statut: ppublish

Résumé

Developments in the understanding of the etiology of cancer have undermined the 1970s concept that chemicals are either "carcinogens" or "non-carcinogens". The capacity to induce cancer should not be classified in an inflexible binary manner as present (carcinogen) or absent (non-carcinogen). Chemicals may induce cancer by three categories of mode of action: direct interaction with DNA or DNA replication including DNA repair and epigenetics; receptor-mediated induction of cell division; and non-specific induction of cell division. The long-term rodent bioassay is neither appropriate nor efficient to evaluate carcinogenic potential for humans and to inform risk management decisions. It is of questionable predicitiveness, expensive, time consuming, and uses hundreds of animals. Although it has been embedded in practice for over 50 years, it has only been used to evaluate less than 5% of chemicals that are in use. Furthermore, it is not reproducible because of the probabilisitic nature of the process it is evaluating combined with dose limiting toxicity, dose selection, and study design. The modes of action that lead to the induction of tumors are already considered under other hazardous property categories in classification (Mutagenicity/Genotoxicity and Target Organ Toxicity); a separate category for Carcinogenicity is not required and provides no additional public health protection.

Identifiants

pubmed: 30660801
pii: S0273-2300(19)30024-8
doi: 10.1016/j.yrtph.2019.01.024
pii:
doi:

Substances chimiques

Carcinogens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-129

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

John E Doe (JE)

Parker Doe LLP, Carpenter Court, Maple Road, Bramhall, Stockport, Cheshire, SK7 2DH, UK. Electronic address: john.doe@parkerdoe.com.

Alan R Boobis (AR)

Centre for Pharmacology & Therapeutics, Toxicology Unit, Department of Medicine, Hammersmith Campus, Imperial College London, London, W12 0NN, UK.

Vicki Dellarco (V)

Independent Consultant, Silver Spring, MD, 20901, USA.

Penelope A Fenner-Crisp (PA)

Independent Consultant, North Garden, VA, 22959, USA.

Angelo Moretto (A)

Dipartimento di Scienze Biochimiche e Cliniche (Department of Biomedical and Clinical Sciences), Università degli Studi di Milano, Milan, Italy.

Timothy P Pastoor (TP)

Pastoor Science Communication, LLC, Greensboro, NC, 27455, USA.

Rita S Schoeny (RS)

Rita Schoeny LLC, Washington DC, 20002, USA.

Jennifer G Seed (JG)

Independent Consultant, Alexandria, VA, 22301, USA.

Douglas C Wolf (DC)

Syngenta Crop Protection, LLC, Greensboro, NC, 27419, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH